Biodegradable Sirolimus-loaded Poly(lactide) Nanoparticles as Drug Delivery System for the Prevention of In-Stent Restenosis in Coronary Stent Application

Abstract

The administration of drugs using biodegradable polymer nanoparticles as carriers has generated immense interest due to their excellent biocompatibility and the prolonged drug release. The scope of this work was to determine the applicability of sirolimus-loaded biodegradable poly(D,L-lactide) (PDLLA) nanoparticles as drug carriers to prevent restenotic processes after stent implantation. The average 250 nm sized 20%(w/w) sirolimus-loaded nanoparticles were extensively characterized with regard to in vitro degradation, biocompatibility and in vitro drug release. The particles show biphasic release kinetics consisting of a short burst release of 50%(w/w) sirolimus payload, followed by a longer, slower release phase, which are desirable for the application as a drug delivery carrier. All presented results exhibit the potential of sirolimus-loaded PDLLA nanoparticles as promising local and sustained drug delivery systems administered intraluminally to reduce in-stent restenosis after stent implantation.

Keywords

in-stent restenosis sirolimus poly(D,L-lactide) nanoparticles human coronary artery smooth muscle cells human coronary artery endothelial cells.

Get full access to this article

View all access options for this article.

References

Ramcharitar, S. , Gaster, A.L. , Daemen, J. and Serruys, P. Drug-eluting Stents, Restenosis and Revascularization , Herz, 2007: 32: 287-295.

Ong, A.T.L. , Aoki, J. , McFadden , E.P. and Serruys, P.W. Classification and Current Treatment Options of In-Stent Restenosis: Present Status and Future Perspectives, Herz, 2004: 29: 187-194.

Regar, E. , Sianos, G. and Serruys, P.W. Stent Development and Local Drug Delivery, Brit. Med.l Bull. , 2001: 59: 227-248.

Mitra, A.K. and Agrawal, D.K. In Stent Restenosis: Bane of the Stent Era, J. Clin. Pathol. , 2006: 59: 232-239.

Ferns, G.A.A. and Avades, T.Y. The Mechanisms of Coronary Restenosis: Insights from Experimental Models, Int. J. Exp. Pathol., 2000: 81: 63-88.

Sousa, J.E. , Serruys, P.W. and Costa, M.A. New Frontiers in Cardiology: Drug-eluting Stents: Part II, Circulation, 2003: 107: 2383-2389.

Sousa, J.E. , Serruys, P.W. and Costa, M.A. New Frontiers in Cardiology: Drug-eluting Stents: Part I, Circulation, 2003: 107: 2274-2279.

Ong, A.T. and Serruys, P.W. Technology Insight: An Overview of Research in Drug-eluting Stents, Nat. Clin. Pract. Cardiovasc. Med. , 2005: 2: 647-658.

Silber, S. When are Drug-eluting Stents Effective? A Critical Analysis of the Presently Available Data, Z. Kardiol., 2004 : 93: 649-663.

10.

Lanzer, P. , Sternberg, K. , Schmitz, K.P. , Kolodgie, F. , Nakazawa, G. and Virmani, R. Drug-eluting Coronary Stent Very Late Thrombosis Revisited, Herz, 2008: 33: 334-342.

11.

Lüscher, T.F. , Steffel, J. , Eberli , F.R. et al. Drug-eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , Circulation , 2007: 115: 1051-1058.

12.

Unverdorben, M. , Vallbracht, C. , Cremers , B. et al. Paclitaxel-coated Balloon Catheter Versus Paclitaxel-coated Stent for the Treatment of Coronary In-stent Restenosis , Circulation, 2009: 119: 2986-2994.

13.

Cremers, B. , Biedermann, M. , Mahnkopf , D. , Böhm, M. and Scheller, B. Comparison of Two Different Paclitaxel-coated Balloon Catheters in the Porcine Coronary Restenosis Model, Clin. Res. Cardiol., 2009: 98: 325-330.

14.

Scheller, B. and Speck, U. Potential Solutions to the Current Problem: Coated Balloon, EuroIntervention, 2008: 4: C63-C66.

15.

Nakano, K. , Egashira, K. , Masuda, S. et al. Formulation of Nanoparticle-Eluting Stents by a Cationic Electrodeposition Coating Technology. Efficient Nano-Drug Delivery via Bioabsorbable Polymeric Nanoparticle-Eluting Stents in Porcine Coronary Arteries , JACC: Cardiovascular Interventions, 2009: 2: 277-283.

16.

Joner, M. , Morimoto, K. , Kasukawa, H. et al. Site-specific Targeting of Nanoparticle Prednisolone Reduces In-stent Restenosis in a Rabbit Model of Established Atheroma, Arterioscl. Throm. Vas., 2008: 28: 1960-1966.

17.

Margolis, J. , McDonald, J. , Heuser , R. et al. Systemic Nanoparticle Paclitaxel (nab-Paclitaxel) for In-stent Restenosis I (SNAPIST-I): A First-in-human Safety and Dose-finding Study, Clin. Cardiol., 2007: 30: 165-170.

18.

Banai, S. , Chorny, M. , Gertz, S.D. et al. Locally Delivered Nanoencapsulated Tyrphostin (AGL-2043) Reduces Neointima Formation in Balloon-injured rat Carotid and Stented Porcine Coronary Arteries, Biomaterials, 2005: 26: 451-461.

19.

Kolodgie, F.D. , John, M. , Khurana , C. et al. Sustained Reduction of In-stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel, Circulation, 2002: 106: 1195-1198.

20.

Cartiera, M.S. , Johnson, K.M. , Rajendran, V. , Caplan, M.J. and Saltzman, W.M. The Uptake and Intracellular Fate of PLGA Nanoparticles in Epithelial Cells, Biomaterials, 2009: 30: 2790-2798.

21.

Desai, M.P. , Labhasetwar, V. , Walter , E. , Levy, R.J. and Amidon, G.L. The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells is Size Dependent , Pharm. Res. , 1997: 14: 1568-1573.

22.

Torchilin, V.P. (2006). Nanoparticles as Drug Carriers , London, Imperial College Press .

23.

Kumar, C.S.S.R. ( 2006). Nanomaterials: Toxicity, Health and Environmental Issues , Weinheim, Wiley-VCH.

24.

Wu, X.S. ( 1995). Synthesis and Properties of Biodegradable Lactic/Glycolic Acid Polymers, New York, Marcel Dekker.

25.

Jain, R.A. The Manufacturing Techniques of Various Drug Loaded Biodegradable Poly(lactide-co-glycolide) (PLGA) Devices, Biomaterials, 2000: 21: 2475-2490.

26.

Lewis, D.H. ( 1990). Controlled Release of Bioactive Agents from Lactides/ Glycolide Polymers, New York, Marcel Dekker.

27.

Tice, T.R. and Cowsar, D.R. Biodegradable Controlled-release Parenteral Systems, Pharm.l Technol., 1984: 8: 26-36.

28.

Marks, A.R. Cellular Functions of Immunophilins, Physiol.l Rev., 1996: 76: 631-649.

29.

Marx, S.O. , Jayaraman, T. , Go, L.O. and Marks, A.R. Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells, Circ. Res., 1995: 76: 412-417.

30.

Poon, M. , Marx, S.O. , Gallo, R. , Badimon, J.J. , Taubman, M.B. and Marks, A.R. Rapamycin Inhibits Vascular Smooth Muscle Cell Migration, J. Clin. Invest., 1996: 98: 2277-2283.

31.

Gallo, R. , Padurean, A. , Jayaraman, T. et al. Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle, Circulation, 1999: 99: 2164-2170.

32.

Morice, M.C. , Serruys, P.W. , Eduardo Sousa , J. et al. A Randomized Comparison of a Sirolimus-eluting Stent with a Standard Stent for Coronary Revascularization, New Eng. J. Med., 2002: 346: 1773-1780.

33.

Morice, M.C. , Serruys, P.W. and Sousa, J.E. A Randomized Comparison of a Sirolimus-eluting Stent with a Standard Stent for Coronary Revascularization ( New Eng. J. Med., 2002 : 346: 1773-1780)), New Eng. J. Med., 2002: 347: 1285.

34.

Moses, J.W. , Leon, M.B. , Popma, J.J. et al. Sirolimus-eluting Stents Versus Standard Stents in Patients with Stenosis in a Native Coronary Artery, New Eng. J. Med., 2003: 349: 1315-1323.

35.

Stolnik, S. , Davies, M.C. , Illum, L. , Davis, S.S. , Boustta, M. and Vert, M. The Preparation of Sub-200 nm Biodegradable Colloidal Particles from Poly (β-malic acid-co-benzyl malate) Copolymers and Their Surface Modification with Poloxamer and Poloxamine Surfactants, J. Control. Release, 1994: 30: 57-67.

36.

Nociari, M.M. , Shalev, A. , Benias , P. and Russo, C. A Novel One-step, Highly Sensitive Fluorometric Assay to Evaluate Cell-mediated Cytotoxicity , J. Immunol. Methods, 1998: 213: 157-167.

37.

Muir, D. , Varon, S. and Manthorpe, M. An Enzyme-linked Immunosorbent Assay for Bromodeoxyuridine Incorporation using Fixed Microcultures, Anal. Biochem., 1990: 185: 377-382.

38.

Bala, I. , Bhardwaj, V. , Hariharan, S. , Sitterberg, J. , Bakowsky, U. and Ravi Kumar, M.N.V. Design of Biodegradable Nanoparticles: A Novel Approach to Encapsulating Poorly Soluble Phytochemical Ellagic Acid, Nanotechnology , 2005: 16: 2819-2822.

39.

Wilhelm, C. , Billotey, C. , Roger, J. , Pons, J.N. , Bacri, J.C. and Gazeau, F. Intracellular Uptake of Anionic Superparamagnetic Nanoparticles as a Function of their Surface Coating, Biomaterials , 2003 : 24: 1001-1011.

40.

Sakurai, I. , Suzuki, T. and Sakurai, S. Cross-sectional View of Myelin Figures, BBA - Biomembranes , 1989: 985: 101-105.

41.

Matter, C.M. , Rozenberg, I. , Jaschko, A. et al. Effects of Tacrolimus or Sirolimus on Proliferation of Vascular Smooth Muscle and Endothelial Cells, J. Cardiovasc. Pharm. , 2006: 48: 286-292.

42.

Nakazawa, G. , Finn, A.V. and Virmani, R. Vascular Pathology of Drug-eluting Stents , Herz, 2007: 32: 274-280.

43.

Finn, A.V. , Nakazawa, G. , Joner, M. et al. Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing, Arterioscl. Throm. Vas., 2007: 27: 1500-1510.

44.

van der Giessen, W.J. , Sorop, O. , Serruys , P.W. , Peters-Krabbendam , I. and van Beusekom, H.M.M. Lowering the Dose of Sirolimus, Released From a Nonpolymeric Hydroxyapatite Coated Coronary Stent, Reduces Signs of Delayed Healing, JACC: Cardiovasc . Interven., 2009: 2: 284-290.